Vaxart (NASDAQ:VXRT) Share Price Crosses Below Two Hundred Day Moving Average - Time to Sell?

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.58 and traded as low as $0.37. Vaxart shares last traded at $0.42, with a volume of 5,497,343 shares traded.

Wall Street Analyst Weigh In

Separately, B. Riley reduced their target price on Vaxart from $2.50 to $2.00 and set a "buy" rating for the company in a report on Thursday, March 27th.

Vaxart Trading Up 19.0%

The company has a fifty day moving average of $0.41 and a two-hundred day moving average of $0.58. The stock has a market capitalization of $115.27 million, a price-to-earnings ratio of -1.23 and a beta of 1.27.

Vaxart (NASDAQ:VXRT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts' consensus estimates of ($0.07). Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%. The company had revenue of $20.88 million during the quarter, compared to analyst estimates of $2.85 million. As a group, sell-side analysts predict that Vaxart, Inc. will post -0.39 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Raymond James Financial Inc. acquired a new position in shares of Vaxart during the fourth quarter worth approximately $129,000. Invesco Ltd. lifted its holdings in shares of Vaxart by 48.6% during the fourth quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company's stock worth $50,000 after buying an additional 24,803 shares during the last quarter. Sequoia Financial Advisors LLC lifted its holdings in shares of Vaxart by 140.9% during the fourth quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock worth $40,000 after buying an additional 35,213 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Vaxart by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company's stock valued at $1,723,000 after purchasing an additional 57,911 shares in the last quarter. Finally, Silverarc Capital Management LLC raised its stake in shares of Vaxart by 7.8% in the fourth quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company's stock valued at $714,000 after purchasing an additional 77,782 shares in the last quarter. 18.05% of the stock is currently owned by institutional investors and hedge funds.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.